Ubs Group Ag Gain Therapeutics, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 8,673 shares of GANX stock, worth $11,101. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,673

Previous 14,023 38.15%

Holding current value

$11,101

Previous $45,000 28.89%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$3.21 - $5.04 $17,173 - $26,964	-5,350 Reduced 38.15%	8,673 $32,000
Q4 2023 Feb 09, 2024	BUY	$2.07 - $3.4 $11,838 - $19,444	5,719 Added 68.87%	14,023 $45,000
Q3 2023 Nov 09, 2023	SELL	$3.19 - $4.68 $3,646 - $5,349	-1,143 Reduced 12.1%	8,304 $27,000
Q2 2023 Aug 11, 2023	BUY	$4.36 - $5.5 $22,419 - $28,281	5,142 Added 119.44%	9,447 $42,000
Q1 2023 May 12, 2023	SELL	$3.18 - $5.16 $9,489 - $15,397	-2,984 Reduced 40.94%	4,305 $20,000

Q4 2022 Feb 08, 2023	BUY	$2.89 - $3.29 $9,152 - $10,419	3,167 Added 76.83%	7,289 $22,000
Q3 2022 Nov 10, 2022	SELL	$3.25 - $4.21 $7,439 - $9,636	-2,289 Reduced 35.7%	4,122 $13,000
Q2 2022 Aug 10, 2022	BUY	$2.56 - $4.56 $5,916 - $10,538	2,311 Added 56.37%	6,411 $23,000
Q1 2022 May 16, 2022	SELL	$3.15 - $5.59 $20,150 - $35,759	-6,397 Reduced 60.94%	4,100 $17,000
Q4 2021 Feb 14, 2022	BUY	$5.3 - $9.24 $19,912 - $34,714	3,757 Added 55.74%	10,497 $57,000
Q3 2021 Nov 15, 2021	BUY	$7.01 - $10.26 $18,506 - $27,086	2,640 Added 64.39%	6,740 $51,000
Q2 2021 Aug 13, 2021	SELL	$8.96 - $15.8 $17,964 - $31,679	-2,005 Reduced 32.84%	4,100 $41,000
Q1 2021 May 12, 2021	BUY	$12.15 - $14.92 $74,175 - $91,086	6,105 New	6,105 $91,000

Others Institutions Holding GANX

# of Institutions

Shares Held

2.58M

Call Options Held

22.2K

Put Options Held

16K

View Full List

About Gain Therapeutics, Inc.

Ticker GANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,883,400
Market Cap $15.2M
Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...

More about GANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account